Skip to main content
Premium Trial:

Request an Annual Quote

Reprocell Acquires BioServe, Reinnervate

NEW YORK (GenomeWeb) – Japanese stem cell products company Reprocell said today that it has purchased 3D cell culture firm Reinnervate and US genomics services firm BioServe.

Sedgefield, UK-based Reinnervate makes the Alvetex line of 3D cell culture products, which will be combined with Reprocell's induced pluripotent stem cells to produce next-generation tools for drug toxicity, neuroscience, and cancer research.

Beltsville, Md.-based BioServe operates a commercial biorepository, which supplies human tissues, serum, and DNA and RNA samples to researchers around the globe. It also provides a variety of genomic services including genotyping, DNA and RNA extraction, gene expression and allelic discrimination using real-time PCR, and molecular diagnostic testing out of its CLIA-certified facility.

Reprocell intends to use its access to the samples in BioServe's respository to generate a wide range of disease-related iPSC lines for use in human cell models.

Financial terms of the acquisitions were not disclosed.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.